Is the 25-year hepatitis C marathon coming to an end to declare victory?
K. T. Ahmed, A. Almashhrawi, J. A. Ibdah, V. Tahan
The paper discusses the progress in hepatitis C treatment, highlighting the shift from interferon-based therapies to direct-acting antivirals with higher efficacy and fewer side effects, and emphasizes the need for global prevention and access.
bioRxiv · Apr 16, 2017Microbiology